12 / 33
El perfil de toxicidad favorece el tratamiento con
agentes hormonales sobre la quimioterapia
Docetaxel
TAX-327
Cabazitaxel
TROPIC
Neuropathy: 32% vs 10%
Neutropenia: 32% vs 22%
Febrile neutropenia: 3% vs 2%
Diarhea: 32% vs 10%
Other: asthenia,
alopecia (65%), nail
toxicity (30%),
disgeusia (18%), mucositis
(20%), peripheral edema (19%)
Neutropenia: 82% vs 58%
Febrile neutropenia: 8% vs 1%
Diarrea: 47% vs 11%
(G3: 6% vs <1%)
Neuropathy: 14% vs 3%
Abiraterone
Enzalutamida
Ra-223
COU-301
AFFIRM
ALSYMPCA
Fluid retention: 31% vs 22%
Hypokalemia: 17% vs 8%
Transaminase elevation: 10% vs 8 %
Diarrea: 18% vs 14%
Neutropenia: 1% vs 1%
Anemia: 23% vs 26%
Cardiac events: 13% vs 11%
Diarrhea: 25% vs 15% (G3: 2% vs 2%)
Febrile neutropenia: 1% vs 1%
Anemia: 31% vs 31%
(G3-4: 13% vs 13%)
Thrombocytopenia: 12% vs 6%
No increase in secondary tumors
Astenia: 34% vs 29%
Epilepsy (5 cases)*
Diarrhea: 21% vs 18%
Cardiac events: 6% vs 8%
Similar porcentaje de toxicidades
G3 entre Abiraterona y
Docetaxel, pero difrente perfil
mHSPC
Cortesía Dr. David Lorente
*Toxicidad neurocognitiva